Cost and Coverage of Originator and Biosimilar Ustekinumab Products in Medicare Part D
This cross-sectional study investigates the cost and coverage of ustekinumab originator Stelara and biosimilar products in 2026 for Medicare Part D.
Authors
- Haiden A. Huskamp (ORCID: https://orcid.org/0000-0002-1860-3956)
- NL Keating
- Stacie B. Dusetzina (ORCID: https://orcid.org/0000-0002-3907-9196)
- Rachel E. Sachs (ORCID: https://orcid.org/0000-0002-0172-3572)
- Grace Castle
- Michael A. Carrier
Institutions
- Rutgers, The State University of New Jersey (US)
- Harvard University (US)
- Vanderbilt University (US)
- Washington University in St. Louis (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-08-17
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.31556
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00